QCG
BIIB icon

Quadrant Capital Group’s Biogen BIIB Stock Holding History

Quadrant Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Sell
8,168
-496
-6% -$91.4K 0.04% 394
2025
Q4 		$1.52M Buy
8,664
+136
+2% +$22.2K 0.05% 350
2025
Q3 		$1.19M Buy
8,528
+356
+4% +$48.1K 0.04% 425
2025
Q2 		$1.03M Buy
8,172
+6,616
+425% +$824K 0.04% 469
2025
Q1 		$213K Buy
1,556
+887
+133% +$127K 0.01% 1269
2024
Q4 		$102K Buy
669
+263
+65% +$44.4K 0.01% 1039
2024
Q3 		$78.7K Sell
406
-77
-16% -$16.1K 0.01% 1215
2024
Q2 		$112K Buy
483
+57
+13% +$12.4K 0.01% 948
2024
Q1 		$91.9K Sell
426
-276
-39% -$64.6K 0.01% 1057
2023
Q4 		$182K Buy
702
+66
+10% +$16.2K 0.02% 645
2023
Q3 		$163K Sell
636
-88
-12% -$23.5K 0.02% 613
2023
Q2 		$206K Sell
724
-5
-0.7% -$1.49K 0.02% 507
2023
Q1 		$203K Sell
729
-111
-13% -$30.7K 0.02% 505
2022
Q4 		$233K Buy
840
+453
+117% +$128K 0.03% 428
2022
Q3 		$103K Sell
387
-108
-22% -$22.9K 0.01% 680
2022
Q2 		$101K Buy
495
+20
+4% +$4.09K 0.01% 634
2022
Q1 		$100K Buy
475
+10
+2% +$2.17K 0.01% 668
2021
Q4 		$112K Sell
465
-168
-27% -$43.2K 0.01% 617
2021
Q3 		$179K Hold
633
– – 0.03% 425
2021
Q2 		$219K Sell
633
-156
-20% -$47.3K 0.03% 357
2021
Q1 		$221K Buy
789
+127
+19% +$34.3K 0.04% 324
2020
Q4 		$162K Sell
662
-29
-4% -$7.48K 0.03% 357
2020
Q3 		$196K Buy
691
+130
+23% +$36.3K 0.04% 264
2020
Q2 		$150K Sell
561
-988
-64% -$297K 0.03% 332
2020
Q1 		$493K Buy
1,549
+302
+24% +$91.6K 0.08% 206
2019
Q4 		$357K Buy
1,247
+287
+30% +$79.6K 0.04% 445
2019
Q3 		$214K Buy
960
+231
+32% +$53.8K 0.03% 562
2019
Q2 		$163K Sell
729
-537
-42% -$124K 0.03% 659
2019
Q1 		$285K Buy
1,266
+732
+137% +$230K 0.05% 375
2018
Q4 		$144K Buy
534
+42
+9% +$13.4K 0.04% 465
2018
Q3 		$159K Buy
492
+5
+1% +$1.72K 0.05% 292
2018
Q2 		$123K Buy
487
+61
+14% +$17.1K 0.04% 349
2018
Q1 		$99K Sell
426
-16
-4% -$4.97K 0.04% 415
2017
Q4 		$127K Buy
442
+36
+9% +$11.5K 0.05% 325
2017
Q3 		$116K Buy
406
+22
+6% +$6.51K 0.05% 341
2017
Q2 		$77K Sell
384
-35
-8% -$9.26K 0.03% 412
2017
Q1 		$101K Sell
419
-34
-8% -$9.61K 0.04% 351
2016
Q4 		$114K Sell
453
-17
-4% -$5.04K 0.06% 233
2016
Q3 		$136K Buy
470
+34
+8% +$10.1K 0.09% 186
2016
Q2 		$99K Buy
436
+147
+51% +$38.7K 0.07% 235
2016
Q1 		$69K Sell
289
-957
-77% -$253K 0.04% 304
2015
Q4 		$376K Buy
1,246
+1,031
+480% +$296K 0.26% 80
2015
Q3 		$58K Sell
215
-491
-70% -$162K 0.04% 371
2015
Q2 		$280K Buy
+706
New +$283K 0.18% 99

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Quadrant Capital Group's BIIB Position: Q1 2026 in Review

Quadrant Capital Group reduced its Biogen (BIIB) stake by 5.7% in Q1 2026, selling an estimated $91.4K and leaving 8,168 shares worth $1.5M. The position accounts for 0.04% of the portfolio, ranked #394.

Quadrant Capital Group first reported a position in BIIB in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.52M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Quadrant Capital Group held 8,168 shares of Biogen worth $1.5M as of Q1 2026.
  • Quadrant Capital Group sold 496 Biogen shares in Q1 2026, an estimated $91.4K.
  • Biogen made up 0.04% of Quadrant Capital Group's portfolio in Q1 2026, its #394 holding.
  • Quadrant Capital Group first reported a position in Biogen in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's Biogen position peaked at $1.52M in Q4 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.